Study of heart and lung function in pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how the cells lining your blood vessels and the pressure in your lungs affect pulmonary arterial hypertension (PAH). It tests a new drug called XBD173 to see if it can help improve your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of PAH that is either unexplained, inherited, linked to connective tissue disease, or caused by certain drugs or a heart defect repaired at least a year ago.
- Your previous right heart catheterization showed specific pressures in your heart and lungs.
- You have an implanted device that monitors your heart rhythm and lung pressure, and you can walk more than 50 meters in 6 minutes.
- You are taking at least two PAH medications and your dose has been stable for at least one month.
- You are willing to have genetic testing and are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
This study looks at how people with pulmonary arterial hypertension (PAH) and certain genetic risks cope and how their bodies respond over time. It may help researchers understand factors linked to better or worse outcomes, and how different people manage the condition.
Hear when a new Pulmonary Artery Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.